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Abstract
Introduction: The unexpected identification of a neural tube defect (NTD) safety signal with preconception dolutegravir (DTG)
exposure in the Botswana Tsepamo birth outcomes study brought into sharp focus the need for reliable data on use of new
antiretrovirals in pregnancy, improved pharmacovigilance systems to evaluate safety of new drugs being introduced into popu-
lations including women of reproductive potential, and balanced risk-benefit messaging when a safety signal is identified.
Discussion: The Tsepamo study NTD safety signal and accompanying regulatory responses led to uncertainty about the most
appropriate approach to DTG use among women of reproductive potential, affecting global DTG roll-out plans, and limiting DTG
use in adolescent girls and women. It also revealed a tension between a public health approach to antiretroviral treatment (ART)
and individual choice, and highlighted difficulties interpreting and messaging an unexpected safety signal with uncertainty about
risk. This difficulty was compounded by the lack of high-quality data on pregnancy outcomes from women receiving ART outside
the Tsepamo surveillance sites and countries other than Botswana, resulting in a prolonged period of uncertainty while data on
additional exposures are evaluated to refute or confirm the initial safety signal. We discuss principles for evaluating and introduc-
ing new drugs in the general population that would ensure collection of appropriate data to inform drug safety in adolescent girls
and women of reproductive potential and minimize confusion about drug use in this population when a safety signal is identified.
Conclusions: The response to a signal suggesting a possible safety risk for a drug used in pregnancy or among women who
may become pregnant needs to be rapid and comprehensive. It requires the existence of appropriately designed surveillance
systems with broad population coverage; data analyses that examine risk-benefit trade-offs in a variety of contexts; guidance
to transform this risk-benefit balance into effective and agreed-upon policy; involvement of the affected community and other
key stakeholders; and a communication plan for all levels of knowledge and complexity. Implementation of this proposed frame-
work for responding to safety signals is needed to ensure that any drug used in pregnancy can be rapidly and appropriately
evaluated should a serious safety alert arise.
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1 | INTRODUCTION
While there is an urgency to bring newer and more potent
antiretroviral drugs developed in resource-rich settings to
resource-limited settings as quickly as possible, evaluation of
the safety of new drugs in pregnancy is often limited to small
pharmacokinetic studies following drug approval. Detection of
less common adverse events in pregnancy, such as birth
defects, requires evaluation of a large number of exposures,
which only occurs when the antiretroviral drug is introduced
into populations including women of reproductive potential,
principally in resource-limited settings. There is a critical need
for reliable data on the safety of new drugs in pregnancy,
improved pharmacovigilance systems in resource-limited set-
tings to evaluate the safety of new drugs that will be widely
used by women of reproductive potential, and balanced risk-
benefit messaging when a safety signal is identified.
These needs have been brought into sharp focus by the
identification of a neural tube defect (NTD) safety signal with
preconception dolutegravir (DTG) exposure in the Botswana
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Tsepamo birth outcomes study. The Tsepamo study was ini-
tially developed to assess whether efavirenz (EFV)-based
antiretroviral therapy (ART) use at the time of conception was
associated with increased NTD risk. It was designed to com-
pare pregnancy outcomes in women living with HIV with
those in women without HIV infection and, for women living
with HIV, to compare pregnancy outcomes by ART regimen
and timing (initiated preconception versus during pregnancy)
[1]. After Botswana modified their national guidelines in 2016
to recommend DTG-based ART as the preferred first-line reg-
imen for adults, the study added objectives to evaluate preg-
nancy outcomes in women receiving DTG. Early data on the
safety of DTG initiated during pregnancy was reassuring [2].
In May 2018, the World Health Organization (WHO)
Guidelines Development Group (GDG) was planning to rec-
ommend transition of most people living with HIV to DTG-
based ART, a regimen with improved efficacy and better toler-
ability and durability compared to many other ART regimens.
It was hoped this change would lead to improved viral sup-
pression rates at the individual, community and global level,
resulting in decreased global HIV incidence [3]. Because the
Tsepamo study was within a few months of evaluating their
primary EFV research question, the investigators agreed to
perform and share with the WHO GDG an early unplanned
analysis of pregnancy outcomes (planned for August 2019)
with preconception DTG initiation, to complement their previ-
ously reported data on DTG initiated during pregnancy.
Unexpectedly, the preliminary results demonstrated a small
but statistically significantly increase in absolute NTD risk in
infants born to women receiving DTG-based ART at the time
of conception (4 NTD/426 exposures, prevalence 0.94%, 95%
confidence interval (CI) 0.37%, 2.4%) compared to infants
born to women receiving non-DTG-based ART at the time of
conception (prevalence 0.12%, 95% CI 0.07%, 0.21%), receiv-
ing EFV-based ART at time of conception (prevalence 0.05%,
95% CI 0.02%, 0.15%), initiating DTG-based ART during preg-
nancy (prevalence 0.00%, 95% CI 0.00%, 0.13%) and women
without HIV (prevalence 0.09%, 95% CI 0.07%, 0.12%) [4].
The public release of a safety alert by regulatory agencies
based on these preliminary data led to uncertainty about the
appropriate approach to DTG use among adolescent girls and
women of reproductive potential, affecting plans for global
DTG roll-out, and limiting DTG use in adolescent girls and
women. This response, along with feedback following the July
2018 WHO interim guidance on DTG, also revealed a critical
tension between individual choice and a public health
approach to ART guidelines, in which a simplified approach
relying on use of the same ART regimen across all adolescents
and adults living with HIV is used to allow universal treatment
access within the context of healthcare systems with highly
constrained capacity and resources [5]. Additionally, this situa-
tion highlighted difficulties in interpretation and clear messag-
ing of an unexpected safety signal with uncertainty about risk.
This was compounded by the lack of comprehensive high-qual-
ity data on pregnancy outcomes from women receiving pre-
conception DTG at sites outside of the Tsepamo surveillance
study or countries outside of Botswana, including low rates of
reporting to the existing Antiretroviral Pregnancy Registry
(APR) [6]. This lack of data has resulted in a prolonged period
of uncertainty while data on additional exposures are evalu-
ated to refute or confirm the initial safety signal.
Regardless of whether the DTG NTD signal diminishes or is
refuted with increased data collection, a better framework for
evaluating and introducing new drugs is needed to ensure
appropriate data collection to inform the drug safety in ado-
lescent girls and women of reproductive potential and mini-
mize confusion when a safety signal is identified. This
challenge is not limited to HIV drugs; many women need
treatment for chronic medical conditions such as epilepsy, dia-
betes and hypertension; should women with such conditions
become pregnant, continuation of their medications is often
required for both foetal and maternal health, despite the fre-
quent lack of data on safety in pregnancy. This lack of data
can result in confusion and difficulty if a safety signal is identi-
fied. Additionally, drugs may need to be used despite the pres-
ence of known risks (e.g. valproic acid may be needed to treat
a epilepsy despite a known association with NTD) [7].
2 | DISCUSSION
2.1 | Proposed principles for assessing new safety
signals
Critical to the evaluation of safety signals are the quality,
interpretability and comparability of additional data, including
the settings in which the data are collected (e.g. the preva-
lence of NTDs varies significantly between countries with and
without food folate fortification); the ability to weigh the mag-
nitude and severity of a potential safety risk in relation to the
magnitude and degree of all potential drug risks and benefits;
the appropriate messaging of drug risks and benefits in preg-
nant women and those of reproductive potential; and involve-
ment of the affected community in such messaging.
2.2 | Earlier availability of preclinical reproductive
toxicity data
Currently, there is limited evidence to inform treatment deci-
sions for women who are pregnant or who may become preg-
nant. Data from reproductive toxicology studies in animal
models have been used to screen for potential developmental/
reproductive hazards of new drugs. However, completion of
reproductive toxicity preclinical studies is not required until
phase III clinical trials are underway; in the absence of such
data, pregnant women are excluded from clinical trials.
However, while negative preclinical reproductive toxicology
test results are reassuring, there is no assurance that negative
results obtained by testing drugs in animals can definitively pre-
dict that a drug will lack teratogenic effects in humans [8]. Simi-
larly, it cannot be concluded that agents teratogenic in animals
will necessarily produce teratogenic effects in humans. For exam-
ple, in utero EFV exposure at plasma concentrations 1.3-times
that of systemic human therapeutic exposure was associated
with central nervous system malformations in cynomolgus mon-
keys, but many years of prospective human pregnancy outcome
data and the recent Tsepamo study findings do not support a ter-
atogenic effect of EFV exposure in human pregnancy [4,9].
2.3 | Inclusion of pregnant women in clinical trials
Pregnant women are excluded from most drug trials [10,11].
Pharmacokinetic studies involving pregnant women represent
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only 1.3% of all phase I trials registered through 2013 [12].
The general exclusion of pregnant women from clinical trials
has been predicated on concerns related to the potential foe-
tal harms of medication used during pregnancy; this fails to
consider the risk of withholding optimal therapies from preg-
nant women because of lack of data. Additionally, general
exclusion of pregnant women from clinical trials shifts the risk
from the clinical trials setting, where there is intensive safety
monitoring, to the clinical care setting, where monitoring is
usually minimal. The resultant lack of a solid evidence-base on
drugs in pregnancy puts pregnant women at risk of potentially
harmful interventions, suboptimal treatment and/or failed pre-
vention of maternal disease [13]. Thus, once initial phase I/II
studies in non-pregnant adults have ruled out substantial
safety issues with a new drug and identified appropriate dos-
ing, it is critical that studies of new drugs that will be used by
women of reproductive potential undergo phase I pharmacoki-
netic and safety studies in pregnancy prior to, instead of many
years after, drug approval [14].
2.4 | Improved post-marketing surveillance and
sentinel site surveillance
The evaluation of the potential association of a drug with birth
defects (and other uncommon adverse pregnancy outcomes
such as stillbirth) necessarily requires adequate post-drug
approval surveillance, because even with early pharmacokinetic
studies, too few pregnant women will have drug exposure prior
to approval to evaluate an infrequent outcome. To rule out a
twofold increase in overall birth defect risk, with a 3% preva-
lence in the general population, 200 preconception/early first
trimester exposures are required; however, for rare defects like
NTDs (0.1% and ≤0.06% prevalence in countries without and
with food folate fortification respectively), at least 2000 pre-
conception/early first trimester exposures are needed to rule
out even a threefold increase in risk (e.g. from 0.1% to 0.3%)
[15,16]. Thus, it is only possible to determine the specific risk
of birth defects or other rare events by having an appropriate
surveillance system in place as new drugs are introduced in
populations including women of reproductive potential.
Post-marketing surveillance to evaluate safety in pregnancy
needs to be of high quality and rapidly generated. Pharmacovigi-
lance databases such as the FDA Adverse Event Reporting Sys-
tem (FAERS) and European Medicines Agency EudraVigilance
include exposure data collected only after the event has occurred
[17,18]. This retrospective enrolment introduces potential bias,
with lack of a denominator for the number of patients exposed to
the drug of interest. Other shortcomings of these databases
include duplicate case reports both within and between data-
bases that may be difficult to identify and limited information
about potential confounders [19]. For HIV drugs, we must priori-
tize improvement of reporting of pregnancies and outcomes to
voluntary reporting databases such as the APR and European
Pregnancy and Pediatric HIV Cohort Collaboration (EPPICC).
However, while the APR is an international registry, 74% of
reports come from the United States and its territories and the
EPPICC study focuses on Europe [6]. Short of compulsory
reporting, funding of additional sentinel site surveillance (like the
Tsepamo study) from low- and middle-income countries, where
most HIV-positive women of reproductive age reside and expo-
sures of concern will occur, is essential. For example, PEPFAR
continues to fund birth outcomes surveillance like the Tsepamo
study in Uganda and Malawi, which will be important as new
antiretroviral drugs are introduced into national programmes
[20]. A standardised variable list and data collection process
would allow for appropriate pooling of data and comparisons
across such databases; for example, the WHO has developed
tools, data forms and training to assist countries in the develop-
ment of birth defect surveillance [21]. Depending on the drug
and extent of anticipated use in pregnancy, there should be a
commitment to evaluating a fixed number of pregnancy out-
comes with preconception exposure to detect rare events within
a specific time after drug approval. Sentinel site surveillance in
geographic areas where high use of the drug of concern is antici-
pated would be important to reach this goal.
2.5 | Comprehensive analysis of risks and benefits
No drug is completely without potential risk for the mother/
foetus; however, untreated or sub-optimally treated maternal
disease may pose a greater risk to the mother and her devel-
oping fetus than maternal use of the drug [13]. Modelling is a
valuable additional modality for providing comparative longer-
term assessment of risk, benefits, and impact of different poli-
cies in a variety of settings, using sensitivity analyses when
risk remains uncertain. For example, two groups have used
modelling to compare use of DTG-based to EFV-based ART in
women of reproductive potential, evaluating risks and benefits
in settings with differing ranges of fertility, contraceptive avail-
ability and use, ART efficacy, tolerability, and antiretroviral
drug resistance, and differing NTD risks with preconception
DTG exposure [22,23]. Both studies enumerated the trade-
offs in terms of risk of NTDs and infant death (which may be
higher with DTG) versus risks of maternal disease progres-
sion, maternal death, perinatal HIV transmission, and transmis-
sion to sexual partners for people living with HIV (which may
be higher with EFV due to lower tolerability and less rapid
viral replication suppression). By explicitly quantifying these
possible trade-offs, models can help inform discussion of risks
and benefits at the population level, but policy decisions must
also account for context-specific and individualized discussions
regarding the relative weighing of each of these potential out-
comes for women and their children.
With a safety signal there are accompanying regulatory obli-
gations to release a safety report to healthcare providers and
the public. However, from a guidelines perspective, in the
absence of a clear or impending public health emergency, a
comprehensive risk-benefit evaluation should be performed to
put the safety signal in context, including drug availability and
need, its effectiveness, toxicity, tolerability, cost and specific
characteristics (e.g. antiretroviral drug resistance barrier and
profile). This evaluation can both inform and frame the data
analysis in terms of impact on individuals and programmes
and should be incorporated into any deliberations over recom-
mendations to be included in public health guidelines.
2.6 | Effective counselling on risks and benefits for
women of reproductive potential
In studies evaluating patient counselling on potential drug ter-
atogenic risks, women of reproductive potential have identi-
fied several elements of effective counselling. Key elements
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include information about the effect of a prescribed drug on
future consequences for their reproductive health regardless
of their current pregnancy intentions; clear and accessible
information regarding potential risks as well as potential bene-
fits of the medication, with repeated emphasis on important
information; and the communication of information in a pri-
vate manner with sufficient time to discuss questions with the
provider [24]. Tools to assist the healthcare provider with
short, concise counselling messages would be important for
high-burden settings where time for a patient-centered
approach may be limited.
2.7 | Critical role of the affected community
A key consideration when a safety signal is identified is the
role of the affected community in decision-making processes.
Women living with HIV have strongly expressed the impor-
tance of ensuring a woman’s right to make her own informed
choice among ART regimen options, and that women should
not be denied access to a beneficial and preferred antiretrovi-
ral drug based on their reproductive potential [25]. It is cru-
cially important that community engagement and support are
sought before recommendations are made to policymakers,
stakeholders and governments. Early and continued commu-
nity consultation and engagement should be part of a safety
signal evaluation and any subsequent guidance and policy rec-
ommendations.
2.8 | Flexibility of guidelines process, allowing for
rapid revision
Guidelines are vitally important in interpreting data and trans-
forming it into recommendations or policy. Following the
uncertainty engendered by the initial reaction to the DTG
safety signal, national guidelines varied considerably in their
recommendations on DTG use in women [5,25]. Guidelines
committees should not rely on a safety signal alone for rare
events but should consider this possible risk within a larger
context, including all relevant risks and benefits as well as the
input of people requiring the drug therapy under considera-
tion. Specifically, the WHO Guidelines process includes consid-
erations of efficacy, safety, the certainty of evidence, cost,
values and preferences of patients and providers, feasibility,
equity and human rights [24]. When an unexpected safety sig-
nal arises, as occurred with DTG in 2018, guidelines processes
need to be flexible to enable rapid collection of new informa-
tion to confirm or refute the signal, to provide considerations
for guidance in the case of a prolonged period of uncertainty,
provide sufficient time to include a consultative process with
the affected community to avoid guidance which may result in
controversy or uncertainty, and allow for rapid revision of guid-
ance as soon as important new information becomes available.
2.9 | Need for clear messaging on risk/benefit for a
range of stakeholders
The public health approach to ART has been predicated on
simplicity and task-sharing with health care workers with less
advanced training. A potential but not yet confirmed safety
signal introduces a layer of complexity that may be difficult to
implement. For example, pending further data to confirm or
refute the DTG safety signal, the current WHO approach calls
for women of reproductive potential to make an informed
choice regarding their ART regimen. Health care workers are
likely to need additional training and sufficient time with each
patient to deliver complicated individual counselling messages
in a consistent way. The ability to make an informed choice
relies upon having alternative regimens available; however,
such alternatives are also required in the event of other toxic-
ities, and need to be accounted for when countries are plan-
ning programmes.
In parallel with guidance and policy there is a need for clear
messaging. This needs to provide a range of levels of simplic-
ity/complexity depending on the audience [26]. Messaging
should achieve uniformity across agencies, including messaging
for country Ministries of Health to help governments imple-
ment strategies and avoid ambiguity in interpretation. Patients
and healthcare providers need to have appropriate and clear
information and materials [27,28]. They need to be able to
assess patient-specific treatment options, communicate risk
and benefits including levels of certainty, and ways to poten-
tially mitigate risk as well as support women-centered deci-
sion-making. Training in these domains is an essential element
of appropriate messaging; increasing treatment literacy is
urgently needed and requires investment and funding.
3 | CONCLUSIONS
The response to a rare safety signal in pregnancy needs to be
rapid and comprehensive. Such a response requires the pre-
ceding existence of appropriately designed surveillance sys-
tems with excellent data quality; data analyses that examine
risk-benefit trade-offs in a variety of contexts; guidance that
can transform this risk-benefit balance into effective and
agreed-upon policy; involvement of the affected community
and other key stakeholders; and a communication plan for all
levels of knowledge and complexity. The involvement of the
community, public health and governmental agencies, guideline
committees, Ministries of Health, academics, funders, and
stakeholders is essential in order to avoid uncertainty and dif-
fering interpretation, and their consequences for providers
and patients. Such systems urgently need to be put into place
so that any drug used in pregnancy can be evaluated rapidly
when introduced and as soon as possible once a serious a
safety alert arises. This will require collaborative efforts and
provision of resources from diverse stakeholders, including
public health and governmental agencies such as WHO, PEP-
FAR and ministries of health; regulatory agencies; pharmaceu-
tical companies; and the affected community.
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